Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $425.3 million.

  • Tg Therapeutics' Non-Current Assets rose 346014.23% to $425.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $487.4 million, marking a year-over-year increase of 90731.59%. This contributed to the annual value of $11.3 million for FY2024, which is 268.81% down from last year.
  • As of Q3 2025, Tg Therapeutics' Non-Current Assets stood at $425.3 million, which was up 346014.23% from $38.7 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Non-Current Assets ranged from a high of $425.3 million in Q3 2025 and a low of $11.3 million during Q4 2024
  • For the 5-year period, Tg Therapeutics' Non-Current Assets averaged around $45.8 million, with its median value being $13.7 million (2021).
  • Per our database at Business Quant, Tg Therapeutics' Non-Current Assets plummeted by 7932.15% in 2023 and then skyrocketed by 346014.23% in 2025.
  • Quarter analysis of 5 years shows Tg Therapeutics' Non-Current Assets stood at $48.7 million in 2021, then tumbled by 48.01% to $25.3 million in 2022, then tumbled by 53.97% to $11.6 million in 2023, then decreased by 2.69% to $11.3 million in 2024, then soared by 3653.06% to $425.3 million in 2025.
  • Its last three reported values are $425.3 million in Q3 2025, $38.7 million for Q2 2025, and $12.2 million during Q1 2025.